|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cryptocurrency News Articles
HOOKIPA Pharma Inc. and Poolbeg Pharma (POLB) May Merge to Create Clinical-Stage Biopharmaceutical Company Focused on Developing and Commercialising Innovative Medicines
Jan 02, 2025 at 05:51 pm
The boards of directors of HOOKIPA Pharma Inc. and Poolbeg Pharma (POLB) announced that they have entered into non-binding discussions
HOOKIPA Pharma (NASDAQ: HOOK) and Poolbeg Pharma (POLB) (NASDAQ: POLB) boards announced they have entered into non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg to create a clinical-stage biopharmaceutical company.
The combined entity will be focused on developing and commercialising innovative medicines for critical unmet medical needs, with a special focus on next-generation immunotherapies for the treatment of cancer and other serious diseases.
In connection with the Potential Combination, HOOKIPA is expected to undertake a 100% primary private placement fundraise of up to approximately $30 million, which will be funded into HOOKIPA immediately following the completion of the Potential Combination.
The proceeds from the private placement will be used to provide sufficient capital for the enlarged business to realise meaningful expected value inflection points.
Coinsilium Group (COIN) (AQUIS: COIN), the Web3 investor, advisor, and venture builder, has entered into a strategic collaboration agreement with investment portfolio company Otomato Inc, a pioneering Web3 technology platform specialising in autonomous agent-based solutions.
The Collaboration aims to leverage Otomato’s cutting edge technologies to maximise the return potential of Coinsilium’s existing and future digital asset treasury holdings.
Given that the market is currently shining a light on COIN, and crypto, it makes sense for it to press ahead on an area which arguably will be the picks and shovels of what will happen next in the digital space: Web3.
Quadrise (QED), a supplier of innovative energy solutions for a cleaner planet, announced the signature of an agreement between the European Climate, Infrastructure and Environment Executive Agency and SEASTARS, a consortium of 17 companies which includes Quadrise.
QED said it was delighted to have joined the SEASTARS consortium, which will demonstrate the benefits of bioMSAR™ and our Blend-On-Board technology to a much wider audience, whilst our participation in the Horizon project will deepen our combined knowledge in this important area of marine decarbonisation.
Although something of a filler RNS, QED is nevertheless reminding us that this autumn was transformational for the company both fundamentally and in terms of the share price, and that the momentum is set to continue.
Contango Holdings (CGO), a company focused on unlocking value from the +2 billion tonne Muchesu coal project in Zimbabwe, has confirmed it has now received its first royalty payment of US$200,000 and expects to receive a further US$800,000 this month.
Combined these will bring total royalty receipts to US$1,000,000 as envisaged and previously reported under the Mineral Royalty Agreement.
CGO said this milestone marks a significant step forward in unlocking the immense value of the Muchesu coal project.
The receipt of our first royalty payment not only underscores the confidence our partners have in the project’s potential but also reinforces our commitment to delivering consistent value for our shareholders. With the operational foundations now firmly in place, we are excited about the continued progress and growth opportunities ahead.
Celadon Pharmaceuticals (CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, has updated on its financial position.
The Company can confirmed the provider of the Committed Credit Facility has now transferred an additional £147k under the Company £1m draw down request.
The Company expects to receive the remaining £103k that is outstanding under the draw down during January 2025.
While we know from Tesco that “Every Little Helps”, what we do not quite know is how CEL’s dribs and drabs will payments help its overall situation, or whether this is too little too late?
To directly support and accelerate the Company’s global licensing and partnership strategy to bring its non-invasive, cost effective, CIZ1B biomarker lung cancer blood test to market in 2025, Cizzle Biotechnology (CIZ), the UK based diagnostics developer, has announced that Professor Dawn Coverley, Founder and Non-Executive Director of Cizzle Biotechnology has, with immediate effect, been appointed Chief Scientific Officer, an executive role on the board of the Company.
While we congratulate the professor on her new role, the main thing that the company has needed since it came to market is an evangelist for the cause, to explain to the market the investment proposition and the importance of what it is doing. Only then will CIZ attain a serious valuation.
Emmerson (EML), the Moroccan focused potash development company, has announced that it has signed a Capital Provision Agreement with a specialist litigation funding firm to provide up to US$11,000,000 in both litigation finance capital and working capital for the Company (the “Funding”) and has confirmed Boies Schiller Flexner LLP as its litigation counsel.
The Company has also put a Management Incentive Plan into place.
After allegedly getting ripped
Disclaimer:info@kdj.com
The information provided is not trading advice. kdj.com does not assume any responsibility for any investments made based on the information provided in this article. Cryptocurrencies are highly volatile and it is highly recommended that you invest with caution after thorough research!
If you believe that the content used on this website infringes your copyright, please contact us immediately (info@kdj.com) and we will delete it promptly.
-
- Solana (SOL) Struggles to Hit $2000 as Competitors Rexas Finance (RXS) and Dogecoin (DOGE) Position to Create Insane Wealth by 2025
- Jan 05, 2025 at 05:25 am
- With its high-speed transactions and scalability, Solana (SOL) is among the most well-known blockchain systems, attracting investor curiosity. Still, despite her promise, Solana finds achieving the $2,000 price mark challenging.
-
- Is Ethereum Still Worth Buying? A Top Trader Claims This ETH Rival is the Best Option For Huge ROI Under $1
- Jan 05, 2025 at 05:25 am
- Ethereum has dropped 7.87% over the past month but has also risen brilliantly, rising 27.41% over the prior two months. These conflicting signals have left buyers wondering whether Ethereum is still worth purchasing. One ETH rival, Rexas Finance (RXS), has nevertheless drawn the interest of a top trader. Under $1, RXS is becoming increasingly popular as the best option for investors looking for massive ROI.
-
- Rexas Finance (RXS): The ADA Rival Under $1 Targeting Double-Digit Prices in 2025
- Jan 05, 2025 at 05:25 am
- While Ripple (XRP) is soaring with impressive gains, Cardano (ADA) displays signals of a possible rebound despite recent declines. Rexas Finance (RXS), an ADA competitor less than $1, is taking the stage with its innovative method of real-world asset tokenization.
-
- The Future of Cryptocurrency: Predictions, Risks, and Investment Strategies for 2025
- Jan 05, 2025 at 05:25 am
- Cryptocurrency Market Projections for 2025 As cryptocurrencies continue to intrigue investors worldwide, we are seeing substantial interest in what the market might hold for Bitcoin and other digital assets by 2025. Numerous experts predict that Bitcoin could reach remarkable highs, potentially exceeding $100,000, contingent on continued market confidence and adoption advancements. Such estimates are fueled by anticipated improvements in blockchain technology, increased institutional investment, and global financial shifts.